Industry News

1 1

Glenmark Pharma: Acid reflux capsules get US FDA nod

Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for generic version of AstraZeneca's Nexium, used to treat acid reflux. Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food & Drug Administrati...

Read More

2 2

Hospitals get PG seats but can’t meet standards

Fake faculty, fake patients, inadequate infrastructure these grievances are common about private medical colleges. They are now cropping up in complaints against private hospitals accredited by the National Board of Examination (NBE) for post-graduate seats. Yet, when a student complained about o...

Read More

3 3

Lupin gets more time from govt to complete project in Indore SEZ

The government has approved a proposal of drug firm Lupin to take more time for completion of its project at Indore special economic zone (SEZ) with proposed investment of Rs 205.69 crore. The decision to give more time was taken by the the Board of Approval (BoA) in its meeting on April 22 here....

Read More

4 4

Bulk drug exports rise as Indian makers cash in on China's regulatory woes

Exports of bulk drugs and intermediates from India grew in double digits during the financial year (FY) 2019, a period that was marked by drug shortages in the global market owing to supply disruptions in China. India's domestic market, too, was plagued by shortages of bulk drugs as the pharm...

Read More

5 5

Pfizer gets U.S. approval for $225,000 a year heart drug

Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel. It is the first approved medicine for the disease in the United States. Analysts are forecasting annual sales to exce...

Read More

6 6

M&A deal value in hospital sector jumped by 155% in FY19

MUMBAI: Despite the stress on performance due to regulatory restrictions, the value of merger and acquisition (M&A) deals in hospital sector jumped by record 155 percent at ?7,615 crore in FY19, a report said Monday. The total value of M&A transactions in the hospital sector in FY19 r...

Read More

7 7

Unichem Labs allergic rhinitis drug gets tentative approval from USFDA

Unichem Laboratories Tuesday said it has received tentative approval from the US health regulator for its generic copy of allergic rhinitis Johnson & Johnson Consumer Inc's Zyrtec-D 12 Hour used for treating allergic rhinitis. The tentative nod by the US Food and Drug Administration (...

Read More

8 8

Dr Reddy's launches generic testosterone gel in US market

Drug maker Dr Reddy's Laboratories Monday said it has launched in the US market its generic version of AndroGel testosterone gel which is used in treating adult males with low or no testosterone due to certain medical conditions.  The company's testosterone gel 1.62 per cent, whi...

Read More

9 9

Sun Pharmaceuticals to set up an ethics committee to oversee corporate governance related matters

Sun Pharmaceuticals managing director Dilip Shanghvi told ET in an email interview that executive director Sudhir Valia “has decided to focus more of his time on pursuits outside Sun, but he continues to be a valuable resource for the company.”  The board has agreed to consti...

Read More

10 10

Lupin, Zydus Pharmaceuticals recall products in the US

New Delhi: Drug major Lupin is recalling 46,700 bottles of Morphine Sulfate extended-release tablets, used to treat severe pain, in the US market, according to a report by the US health regulator. Lupin Somerset is recalling the drug in various strengths due to "failed impurities/degradation...

Read More

11 11

What we had done for India, we are now doing for US: Umang Vohra, MD, Cipla

Cipla MD Umang Vohra moved to India from Dr Reddy’s in the US to run the former’s finance function in 2015. Within a year he was named CEO and MD. In an interview with Suman Layak, Vohra explains his strategy of taking Cipla products to global markets. Edited excerpts:  What ...

Read More

12 12

USFDA makes 'certain' observations for Torrent Pharma's Indrad plant

Drug firm Torrent Pharmaceuticals Friday said the US health regulator has made 'certain' observations after inspection of its Indrad facility in Gujarat. The audit at Indrad plant of the company was carried out by the United States Food and Drug Administration (USFDA) in April.  ...

Read More

13 13

Cloudnine Hospitals appoints Raviganesh Venkataraman as CEO

Bengaluru-headquartered private-equity backed Cloudnine, which runs a chain of maternity, childcare and fertility care hospitals, has announced the appointment of Raviganesh Venkataraman as its Chief Executive Officer.  Akash Malik, outgoing CEO has been with the Group for six years and ...

Read More

14 14

USFDA retains OAI status for Indoco's Goa plant

New Delhi-Drug firm Indoco Remedies Wednesday said the US health regulator has retained Official Action Indicated (OAI) status for its Goa plant and may impact approval of pending applications from this facility.  "The United States Food and Drug Administration (USFDA) retains the O...

Read More

15 15

Lupin's Pithampur facility may face regulatory action, says USFDA

NEW DELHI: Drug maker Lupin Tuesday said the US health regulator has cautioned that the firm's Pithampur facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed. The compan...

Read More

16 16

Japans M3 acquires majority share in Bengaluru based DailyRounds

Bengaluru: Japan-based M3, Inc., an online platform for medical professionals, has acquired a majority stake in Bengaluru-based Neuroglia Health Private Limited (NHPL), a provider of mobile and web-based applications for doctors and medical students, for an undisclosed amount. Neuroglia Healt...

Read More

17 17

Alembic Pharma gets USFDA nod for 2 generic products

Drug firm Alembic Pharmaceuticals Monday said it has received approvals from the US health regulator for its Teriflunomide tablets and Tobramycin ophthalmic solution. The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug applica...

Read More

18 18

Torrent Pharma recalls over 10.78 lakh bottles of hypertension drug from US

Drug firm Torrent Pharmaceuticals Inc is recalling over 10.78 lakh bottles of hypertension treatment tablets from the US and Puerto Rico on account of deviations from current good manufacturing norms, as per a report of the US health regulator.  The US-based arm of Torrent Pharmaceutical...

Read More

19 19

Local pharma companies to challenge MNCs in pneumonia vaccine space

The duopoly of pneumonia vaccines in India is in for some shake-up soon, as homegrown players like Aurobindo Pharma, Cadila Healthcare (Zydus Cadila), and Serum Institute are readying their vaccine candidates. The Indian market is at present dominated by GlaxoSmithKline Pharma and Pfizer. Ind...

Read More

20 20

Regulator directs drug manufacturers to incorporate new recorded adverse effects in leaflets

New Delhi: The Drug Controller General of India (DCGI) has written to all state drug regulators to direct manufacturers of certain antibiotics and anti-psychiatric drugs to include their new recorded adverse effects in the leaflets inside the package to promote patients' safety.  The...

Read More

21 21

Granules India gets USFDA nod for pain relief drug

Drug firm Granules India Thursday said it has received approval from the US health regulator for Acetaminophen tablets, used for temporary pain relief.  The approved product is bioequivalent to the reference listed drug product (RLD), Tylenol tablets, extended release.  The US F...

Read More

22 22

Hair in one vail, Aurobindo recalls 88k Lidocaine injections from US

Aurobindo Pharma Ltd has initiated recall of 88,600 vials of Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL) from USA market as one of the vials contained a strand of hair, the US Food and Drug Administration said.  According to a notification put up by the US Drug regulator in it...

Read More

23 23

Government invites initial bids for strategic sale of IMPCL

NEW DELHI: The government has invited initial bids for selling its entire stake in Indian Medicines Pharmaceutical Corporation Ltd (IMPCL).  IMPCL is engaged in manufacture and supply of 'ayurvedic' and 'unani' medicines and is under the Ministry of AYUSH.  The g...

Read More

24 24

Many essential drugs priced much higher than manufacturing cost: WHO

Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering ...

Read More

25 25

Ayushman Bharat package rates revision on radar

Kolkata: The contentious issue of package rates of Central government's Ayushman Bharat scheme may be resolved after the Lok Sabha election, a senior official of a private hospital chain said here on Friday.  The Indian Medical Association (IMA) has demanded a "reasonable and fa...

Read More

26 26

Indian execs named in US pharma case

Connecticut, which is leading a multistate investigation of an anti-trust lawsuit against 18 generic pharma companies, including five Indian firms, over price cartelisation on Wednesday said it has unsealed some key details of possibly the “largest cartel case in the history of the United S...

Read More

27 27

Lupin launches generic antidepressant tablets in US

Drug firm Lupin Wednesday said it has launched generic antidepressant Fluoxetine tablets in the American market.  The company has launched its Fluoxetine tablets USP in the strength of 60mg after having received an approval from the United States Food and Drug Administration (USFDA) earl...

Read More

28 28

CPPIB eyes emerging companies in financial services, healthcare & education

MUMBAI: After partnering with storied brick-and-mortar names such as Larsen & Toubro and Bharti, the Canada Pension Plan Investment Board (CPPIB) is looking to back emerging champions across financial services, healthcare, commerce and education that are overlaying technology to define and de...

Read More

29 29

BainPiramal led fund offers Panacea a Rs 992 crore bail out deal

MUMBAI: The Bain Capital and Ajay Piramal group-run distressed asset fund India Resurgence Fund Monday said it will invest Rs 992 crore in New Delhi-based pharma player Panacea BiotecNSE -2.99 % which is facing financial headwinds.  The joint venture fund has been active in the pharma bu...

Read More

30 30

Government notifies new rules for drugs and clinical trials

Aimed at promoting clinical research in the country, the Health Ministry on Monday notified New Drugs and Clinical Trials Rules, 2019 reducing the time for approving applications to 30 days for drugs manufactured in India and 90 days for those developed outside the country.  The new rule...

Read More

31 31

Genes2Me Bringing New Healthcare Paradigm with Genomics

Genes2Me, India’s first diagnostic chain to bridge clinical diagnostics with genomics has reinvigorated the preventive healthcare sector in the country. Genes2Me has evolved as a game changer in the field of molecular testing by yielding health statistics of today and suitable lifestyle gui...

Read More

32 32

Ayushman Bharat beneficiaries can soon access best cancer care from network of specialists

NEW DELHI: Ayushman Bharat beneficiaries will soon be able to seek the best advice from a network of cancer specialists digitally linked across the country, and won’t have to travel long distances to consult an expert.  The National Health Authority is in talks to partner with the ...

Read More

33 33

Pharma MNCs wary of illegal import of innovator drugs

Hyderabad: Multinational pharmaceutical companies are crying foul over the illegal import of innovator drugs worth crores of rupees into the Indian market from neighbouring countries and sold by pharmacies, distributors and websites.  The Organisation of Pharmaceutical Producers of India...

Read More

34 34

USFDA classifies Lupin's Somerset facility as 'Official Action Indicated'

NEW DELHI: Drug major LupinNSE 0.82 % Saturday said it has been cautioned by the US health regulator that its Somerset (New Jersey) facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is...

Read More

35 35

Cold wave across US to bring big business for Indian drug companies

The cold wave in the US may bring big business for domestic pharma firms. The cold conditions there have resulted in spike in flu cases. Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication (Oseltamivir) in the US market, are likely to benefit. ...

Read More

36 36

Suven Life Sciences to set up subsidiary in US to infuse $75 million

NEW DELHI: Suven Life Sciences  Saturday said it will create a wholly-owned subsidiary in the US and will infuse USD 75 million (about Rs 525 crore) in its new business.  The board of directors at its meeting held on Saturday has taken on record the approval for creation of wholly o...

Read More

37 37

GST relief for pharma samples discount offers

NEW DELHI: Many businesses have been grappling with basic questions on discounts and freebies. Does a free toothbrush with a tube of toothpaste attract GST? Or, how much GST will be levied on a charger that is part of a pack of mobile phone purchased by customers?  Close to two years aft...

Read More

38 38

Suven plans to buy US based Rising Pharmaceuticals assets

Biopharmaceutical firm Suven LifeNSE 0.06 % Sciences Ltd on Friday said it has entered into an asset purchase agreement to buy the assets of US-based Aceto Corporation's Rising Pharmaceuticals through its joint venture partner Shore Suven Pharma Inc.  Suven Life SciencesNSE -2.26 % t...

Read More

39 39

Whistleblower says Sun Pharma gave doctors gifts through a subsidiary

A whistleblower has alleged that Sun PharmaNSE 0.86 % Ltd used its subsidiary Aditya Medisales Ltd (AML) to give gifts — including personalised websites and online promotion — to doctors in violation of pharma industry guidelines.  Conversations with the whistleblower, as wel...

Read More

40 40

US FDA chiefs exit could impact Indian pharma

The abrupt exit of the US FDA commissioner Scott Gottlieb after a nearly 2-year stint under the Trump administration throws Indian pharma into uncertainty on what would be the stance of the next commissioner on generics drug pricing, pace of approvals and regulatory inspections.  India, ...

Read More

41 41

India requires pragmatic compulsive licensing system Cipla

The government needs to have a compulsive licensing system for essential drugs and look at locally manufacturing non-patented medicines, Cipla chairman Y K Hamied said Wednesday.  "For healthcare what India requires is a pragmatic compulsive licensing system. My own reading is what ...

Read More

42 42

Ayushman Mitra can be brought under national health agency payroll: Think tank associated with BJP

Volunteers appointed to assist patients under the Ayushman Bharat scheme could be brought under its payroll to fix a direct accountability, according to recommendations of a think tank associated with the BJP. The Public Policy Research Centre conducted an assessment of first phase of implementat...

Read More

43 43

Glenmark Pharmaceuticals gets USFDA nod for hypertension drug

Glenmark Pharmaceuticals Tuesday said it has received final approval from the US health regulator for Telmisartan and Hydrochlorothiazide tablets, used to treat high blood pressure (hypertension). The approved products is a generic version of Boehringer Ingelheim Pharmaceuticals Inc's Mic...

Read More

44 44

Government plans to colour code generic drugs

NEW DELHI: In a move to promote low-cost generic medicines, the government plans to colour code such drugs to enable consumers to differentiate between generic medicines and other drugs and take an informed decision while purchasing them from chemists. Apart from colour coding, the government is ...

Read More

45 45

Scientists may have found a solution that can put an end to drug injections

Here was the challenge for bioengineers: Find a way for patients to take drugs — like insulin or monoclonal antibodies used to treat cancers and other diseases — without injections. The medicines are made of molecules too big to be absorbed through the stomach or intestines; in an...

Read More

46 46

Sun Pharma surges 5percent as US arm Taro posts healthy December quarter results

Shares of Sun Pharmaceuticals were trading 5 per cent higher at Rs 436 on the BSE in intra-day trade on Thursday after its US subsidiary Taro Pharmaceutical reported strong results for the quarter ended December 2018. Taro Pharmaceuticals posted net sales of $176.4 million, an increase of $20...

Read More

47 47

Strides Pharma Science gets EIR for Bangalore facility

NEW DELHI: Drug firm Strides Pharma Science Wednesday said it has received the Establishment Inspection Report (EIR) from the US health regulator for its formulations facility in Bangalore. "The company's formulations facility (KRSG Gardens) in Bangalore which was inspected by the US...

Read More

48 48

Lupin posts Q3 loss of Rs 152 crore on litigation over blood pressure drug

Drugmaker Lupin Ltd posted a surprise quarterly loss on Wednesday after taking a one-time charge related to litigation over a blood pressure drug. Lupin made a provision of Rs 342 crore ($47.7 million) after the General Court of the European Union in December upheld a 2014 European Commission...

Read More

49 49

As prices of generics slide, pharma firms shift focus to specialty drugs

NEW DELHI: Indian drug makers are shifting focus from their once lucrative generics medicines to specialty drugs amid continued price erosion in its biggest market, the US. The focus on specialty medicines has been accelerated by measures taken by the Food and Drug Administration of the US (U...

Read More

50 50

TPG Growth to invest 30 million dollars in API maker Solara Active Pharma

TPG Growth, the growth capital investment arm of US-based private equity giant TPG, has said it will invest $30 million in Solara Active Pharma, a manufacturer of active pharmaceutical ingredients (API). Solara has a network of customers including several top global generic companies in the U...

Read More

51 51

Drone ports in hospitals soon to allow quick transportation of organs Jayant Sinha

NEW DELHI: Drones may soon be able to beat Indian cities’ notorious traffic and ensure speedy transportation of organs between hospitals, a possibility without creating green corridors or special road routes. Union minister of state for aviation Jayant Sinha said the authorities concerned, ...

Read More

52 52

Faulty medical devices Patients can seek compensation

NEW DELHI: Indian patients suffering due to faulty medical devices may soon be empowered to demand compensation for health problems caused by such products from the company making or importing them.    Drugs Technical Advisory Board (DTAB), the country’s apex drugs advisor...

Read More

53 53

Government plans database of drugs to prevent use of similar brand names

NEW DELHI: The government is considering a databank for all medicine brands to prevent pharmaceutical companies from using the same or similar looking and sounding brand names for drugs, especially those used to treat different conditions, senior officials close to the development said.  ...

Read More

54 54

Medicines may soon have gluten labelling on packaging

New Delhi: Drugmakers may be asked to declare on their packagings whether a medicine contains gluten, a step that health officials say would provide immediate relief to millions of Indians suffering from celiac disease, an autoimmune disorder in which the body mistakenly reacts to gluten. India&r...

Read More

55 55

Lupin CFO quits to pursue opportunities outside pharma

MUMBAI: Ramesh Swaminathan, Chief Financial Officer of Lupin Pharma, has quit the company to pursue opportunities outside of pharmaceutical industry, the company said in a statement to the exchanges. Swaminathan was part of Lupin for the last 12 years where he was also a whole time director. ...

Read More

56 56

Amway enters herbals space

NEW DELHI: The India arm of the $8.6 billion direct selling company Amway Corp, which sells a range of personal care and household products, has entered the rapidly growing herbals skincare market, its first such brand in the category.    “We are watching this space very c...

Read More

57 57

Alembic Pharma gets USFDA nod for Alembic Pharma

NEW DELHI: Alembic Pharmaceuticals Monday said its joint venture Aleor Dermaceuticals has received approval from the US health regulator for Xylocaine ointment, used for temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin and insect bites.  &quo...

Read More

58 58

Indonesias PT Bio Farma gets cleanchit in polio vaccine contamination case

New Delhi: Drug inspectors working to unearth the mystery behind the contamination of polio vaccines have found nothing amiss at the Indonesian bulk-manufacturer, said two people aware of the matter, bringing the spotlight back to the Indian firm that supplied the final vaccine to an official imm...

Read More

59 59

Apollo Hospitals to hive off retail pharmacy business into new company

CHENNAI: As a part of its restructuring exercise, Apollo Hospitals Enterprise on Wednesday said that it is divesting its front-end pharmacy business to Apollo Pharmacy for a lump sum cash consideration of Rs 527.8 crores.  Apollo Pharmacy (APL) will be a wholly owned subsidiary of Apollo...

Read More

60 60

Suven Life gets product patents from Australia Hong Kong

NEW DELHI: Suven Life Sciences Tuesday said it has been granted a product patent each by Australia and Hong Kong for a new chemical entity (NCE) for the treatment of disorders associated with neuro-degenerative diseases.  These patents are valid till 2036 and 2033 respectively, the compa...

Read More

61 61

IHH CEO Tan See Leng to join Fortis board

IHH Bhd chief executive officer Tan See Leng is expected to join the board of Fortis Healthcare today following the Malaysian healthcare group's purchase of shares worth Rs 4,000 crore in India's second largest hospital chain, ET has learnt.  IHH, which is taking charge of Fortis...

Read More

62 62

Lupin gets EIR from USFDA for its Nagpur facility

Drug firm Lupin said on Monday that it has received an establishment inspection report (EIR) from the US health regulator post the inspection of its Nagpur facility.  "The United States Food and Drug Administration (USFDA) conducted a pre approval inspection for its Phenytoin Sodium...

Read More

63 63

Zydus Cadila gets USFDA nod for antifungal ointment

Zydus Cadila Monday said it has received final approval from the US health regulator to market Nystatin and Triamcinolone Acetonide Ointment, used in the treatment of fungal skin infections.  Cadila has received the final approval from the United States Food and Drug Administration (USFD...

Read More

64 64

Cipla gets USFDA nod for antiviral eye infection drug for AIDS patients

Drug major Cipla Monday said it has received final approval from the US health regulator for Valganciclovir tablets, used in the treatment of viral eye infection in AIDS patients.  Valganciclovir tablets are used in the treatment cytomegalovirus infection (serious viral eye infection of ...

Read More

65 65

Pharma lobby for hiking cost of drugs under govt price control

New Delhi: A sharp rise in prices of commonly used drug raw materials from China has prompted a pharmaceutical industry lobby to seek higher retail prices of medicines that are under government price control. The group has warned that failure to do so may lead to a shortage of medicines. With...

Read More

66 66

IIT Roorkee researchers make headway in cancer therapy

Indian Institute of Technology (IIT) Roorkee researchers have developed fluorescent carbon nanodots that can serve as “theranostic” (therapeutic and diagnostic) agents for cancer.  Led by P Gopinath, a team of IIT Roorkee researchers, have developed nanosized (having ...

Read More

67 67

Clinical trials on Ayurvedic medicine against dengue underway: Shripad Naik

NEW DELHI: Clinical trials on Ayurvedic medicine against dengue are in progress and it will be launched at the earliest possible time, Union Minister of State for AYUSH Shripad Naik said Sunday.  Rajesh Kotecha, secretary of AYUSH ministry, said the medicine is expected to be rea...

Read More

68 68

NPPA fixes retail price of 68 drug formulations

New Delhi: Drug price regulator NPPA Friday fixed prices as well as revised ceiling and retail prices of 68 formulations, including those used for treatment of diabetes, blood pressure and HIV. The National Pharmaceutical Pricing Authority (NPPA) said while the retail price of 55 sche...

Read More

69 69

True North in talks to buy into Glenmarks API biz for Rs 1500 cr

MUMBAI: Private equity firm True North Capital is in advance talks with Glenmark Pharmaceuticals to buy upto 20 percent stake in the active pharmaceuticals ingredient (API) business of the Mumbai-based firm for about Rs 1200 crore - 1500 crore, in what could be yet another investment in India&rsq...

Read More

70 70

Pharma exports up 3 pc to 17.3 billion dollars in 2017 18

India's pharmaceutical exports grew merely 3 per cent to USD 17.3 billion in 2017-18 due to increasing regulatory concerns and pricing pressures in the global markets, including the US. The sector's exports in 2016-17 had declined to USD 16.7 billion as against USD 16.9 billion in the pre...

Read More

71 71

Indias spending on health sector has grown Nadda

India's expenditure on the health sector has risen from 1.2 per cent of the GDP in 2013-14 to 1.4 per cent in 2017-18, Health Minister J P Nadda said today.  He was addressing the concern of members of the Rajya Sabha about the low share of funds spent on healthcare as a percentage o...

Read More

72 72

Telangana plans countrys first biopharma hub

Telangana government proposes to set up India’s first Biopharma-Hub to provide support to the biopharma research and development activities, featuring a scaleup manufacturing facility and a turnkey incubator/ lab space module.  The proposed facility, spread across 40,000 square fee...

Read More

73 73

Governments drug price caps may trigger showdown with US

MUMBAI: US pharma biggies are at the receiving end of the Donald Trump administration’s ire due to rising drug prices in that country, and this may cause anxiety for the Indian government as well as domestic generic companies. Unlike in the past, Washington is increasingly putting the blame...

Read More

74 74

TPG Capital to buy into Sai Life Sciences

MUMBAI: TPG Capital said on Wednesday it will acquire a significant minority stake in Hyderabad-based Sai Life SciencesNSE 0.33 %, in what could be seen as renewed interest in India’s pharma and life-sciences space from large foreign institutional investors.  Though both companies ...

Read More

75 75

Oxytocin ban Drug makers report panic buying by hospitals

MUMBAI: The government’s decision to restrict the production and sale of oxytocin, a crucial hormone used on pregnant women for the induction of labour and stall postpartum bleeding, has sent hospitals to a panic buying mode, industry executives said, even as at least one manufacturer has a...

Read More

76 76

Working group may vet plan to check fake drugs

NEW DELHI: India’s central drug regulator is creating a working group to critically appraise its proposal to set up a “trace and track” mechanism to weed out fake medicines from the market using unique codes.  The working group, comprising pharmaceutical association rep...

Read More

77 77

Panel recommends ban on 343 fixed dose combination medicines

NEW DELHI: In a move that could potentially deliver a big blow to pharmaceutical companies in India, an apex advisory board on drugs approved a report backing the health ministry’s decision to ban many fixed dose combination (FDC) medicines.  The report, prepared by a sub-committee...

Read More

78 78

Unichem Labs gets USFDA nod for asthma drug

Drug firm Unichem Laboratories today said it has received final approval from the US health regulator for its Montelukast chewable tablets used for prevention and treatment of asthma.  The company has received final abbreviated new drug application (ANDA) approval from the United States ...

Read More

79 79

Suven Life gets product patents from India S. Korea and Singapore

Suven Life Sciences today said it has been granted a product patent by India, Singapore, South Korea and Israel each for a new chemical entity (NCE) used in treatment of disorders associated with neurodegenerative diseases.  These patents are valid through 2031, 2034, 2034 and 2036 respe...

Read More

80 80

Government plans to cap drug prices at first point of sale

NEW DELHI: The government is considering a proposal to make essential medicines more affordable by capping prices at the first ‘point of sale’ rather than retail price — a move intended to curb margins offered to hospitals, distributors and doctors to push particular brands.&nbs...

Read More

81 81

Dr Reddys gets EIR from USFDA for 2 units at Medak in Telangana

New Delhi: Drug firm Dr Reddy’s Laboratories on Thursday said it has received establishment inspection report (EIR) from the US health regulator for its two units at Medak district in Telangana. In an earlier filing to the bourses on 9 March, the drug firm had said it had received five ...

Read More

82 82

Lupin Mylan team up for biosimilar Etanercept

MUMBAI: US drug maker Mylan and India's Lupin 0.93 % have come together to market the biosimilar drug Etanercept in Europe, Australia, New Zealand and Asia as both the companies look at expanding their presence in the next wave of drug business. Etanercept is indicated to treat certain autoim...

Read More

83 83

NITI Aayog to set up subgroup to study treatment pricing under Ayushman Bharat

NEW DELHI: Niti Aayog will soon set up a sub-group to look into the complaints of private hospitals regarding pricing of treatment of key ailments proposed by the government under the Prime Minister's flagship health insurance scheme Ayushman Bharat.  The government has come out with...

Read More

84 84

Genomic tests for cancer split oncologists

MUMBAI: Some of India’s leading oncologists have raised doubts over the utility of the tests like Oncotype DX genomic test, which assesses how a cancer is likely to respond to treatment, saying it increases the cost of treatment without yielding clear benefits while others have expressed th...

Read More

85 85

Oxytocin formulations ban to come into effect from July 1

From July 1, no private manufacturer will be allowed to manufacture Oxytocin for domestic use.  Oxytocin is a naturally-occurring hormone that causes uterine contractions during labour and helps new mothers lactate.  But its misuse is widespread in the dairy industry where livestock ...

Read More

86 86

USFDA approves first product from Glenmarks US plant

Glenmark Pharmaceuticals today said the US health regulator has approved the first product from its Monroe, North Carolina based manufacturing facility.  The US Food and Drug Administration (USFDA) has provided its first supplemental Abbreviated New Drug Application (ANDA) approval for t...

Read More

87 87

Lupin Japans NichiI ko tie up to distribute biosimilar drug

New Delhi: Lupin Ltd, India’s third-largest drug maker, on Monday said it has tied up with Japan’s Nichi-Iko for the distribution, promotion and sale of Lupin’s recently filed biosimilar Etanercept in Japan. Etanercept is used for the treatment of several auto immune disease...

Read More

88 88

Novo Nordisks oral diabetes drug beats Jardiance in study

LONDON/COPENHAGEN: Novo Nordisk said data from a large final-stage study of a pill it hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance. The success of the oral form of the drug, known gene...

Read More

89 89

Glenmark Pharma launches generic version of asthma drug in Denmark

NEW DELHI: Glenmark Pharmaceuticals 2.17 % Europe Ltd has launched a generic version of Seretide Accuhaler, used to treat asthma, in Denmark.  The product was developed by Celon Pharma and Glenmark has marketing and distribution rights for the product across 15 European countries.  ...

Read More

90 90

World Health Organisation publishes its first essential diagnostics list

NEW DELHI; The World Health Organisation (WHO) has published its first 'essential diagnostics list', a catalogue of tests needed to diagnose the most common conditions as well as a number of global priority diseases.  The step was taken to address the problem of people's inab...

Read More

91 91

USFDA completes inspection of Lupin s Nagpur plant

New Delhi: Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.  In a BSE filing, Lupin "announced successful completion of an inspection carried out by the United States Food and Drug Administration (...

Read More

92 92

Govt planning unique codes to check menace of fake medicines

New Delhi: India’s highest advisory body on drugs will discuss a mechanism to end the menace of fake medicines at a meeting on 16 May. According to the proposal to be discussed at the Drug Technical Advisory Board meeting, consumers will be able to check whether the medicines that they ...

Read More

93 93

Aurobindo Pharmas arm recalls 2 antibiotic injections from US

AuroMedics Pharma LLC, a US subsidiary of Aurobindo Pharma Ltd,has initiated voluntary recall of two lots each of two injections from the US market followingcustomer complaintsabout presence of particles in the vial.  The fresh recall follows a recent withdrawal of over 1.5 million injec...

Read More

94 94

China s plans to import Indian drugs fail to enthuse Indian pharmaceutical firms

China much-publicised announcement to slash tariffs on 28 medicines, including cancer drugs from India, has failed to create any buzz among the Indian pharmaceutical firmshere as exports to China are possible only after lengthy field trials and approvals, which could take years, an official at an...

Read More

95 95

Cipla gets USFDA nod for generic equivalents of Vazculep Aromasin

New Delhi: Drug major Cipla has received final approval from the US health regulator for generic equivalent of Avadel’s Vazculep, West Ward Pharm Corp’s Phenylephrine Hydrochloride injection and Pfizer’s Aromasin. In a regulatory filing, Cipla said “it has received fin...

Read More

96 96

Abbott discontinues Xience Alpine stents in India

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) on Thursday permitted Abbott Healthcare Pvt Ltd to discontinue selling its premium metallic stent Xience Alpine Premium from the Indian market. Rattled by the regulatory intervention on stent prices, the US healthcare giant had a...

Read More

97 97

Indian scientists using artificial intelligence to predict early onset of Alzheimers

New Delhi: Indian scientists are using artificial intelligence (AI) to develop a smart diagnostics system to predict the onset of Alzheimer’s disease early. Professor Pravat Mandal and his group at the National Brain Research Centre (NBRC), and Neuroimaging and Neurospectroscopy Laborat...

Read More

98 98

Glenmark gets USFDA nod for skin ointment

New Delhi: Glenmark Pharmaceuticals on Wednesday said it has received final approval from the US health regulator for Tacrolimus ointment used for treating atopic dermatitis (eczema). Glenmark Pharmaceuticals Inc. USA has been granted final approval by the United States Food and Drug Administ...

Read More

99 99

AstraZeneca to invest $90 million in India over next 5 years

New Delhi: Biopharmaceutical firm AstraZeneca today said it will invest USD 90 million (around Rs 590 crore) in India over the next five years.  The announcement follows signing of a bilateral innovation partnership for a sustainable future between Sweden and India, AstraZeneca said in a...

Read More

100 100

Narayana Health unveils latest cancer radiation therapy technology Versa HD

The Indian Council of Medical Research (ICMR) says India is exper disease by 202cted to register over 17 lakh new cases of cancer and over 8 lakh deaths because of the kille0.  East and North-East India are not immune to this fact and are reporting substantial number of cancer cases, acc...

Read More

101 101

Apax Partners acquires Healthium MedTech for $350 million

Mumbai: Apax Partners Llp has acquired Bengaluru-based medical devices company Healthium MedTech Pvt. Ltd (formerly known as Sutures India). The London-based private equity (PE) fund has acquired close to 100% stake from existing shareholders, including TPG Growth, CX Partners, and founding s...

Read More

102 102

India to overhaul drug price control system

New Delhi: The government is planning to overhaul the existing system of fixing drug prices in the country. The matter will be discussed at a meeting on 10 April at the Prime Minister’s Office (PMO) with experts from central government think tank NITI Aayog, the department of pharmaceut...

Read More

103 103

US may revoke special tariff if India continues pricing control on medical devices

The US Trade Representative (USTR) is considering to revoke special tariff provided to India if it continues with its pricing policy on medical devices manufactured by American companies, two people aware of the development told ET.  The USTR representatives, who are expected to visit In...

Read More

104 104

Getting rid of tuberculosis

Global consumption of antibiotics increased by 65% between 2000 and 2015, according to a study by Proceedings of the National Academy of Sciences in the US. The growth has been especially high in India, which has doubled its antibiotic consumption. In light of the rising global concerns about dru...

Read More

105 105

ChrysCapital set to acquire 10percent in Mankind for $350 million

ChrysCapital, along with lirtnmited paers GIC of Singapore and CPPIB of Canada, is set to write the largest private equity cheque in the Indian pharmaceutical space as it finalises a $350-million investment in Mankind Pharmaceuticals for a 10% stake, said people directly aware of the matter. If i...

Read More

106 106

Dr Reddys launches generic nausea drug in US

Dr Reddy's Laboratories today said it has launched Palonosetron Hydrochloride Injection, used in treating acute nausea and vomiting, in the US market. The Hyderabad-based firm launched the product after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Labs...

Read More

107 107

Alembic Pharma gets 3 observations from USFDA for Gujarat plant

New Delhi: Alembic Pharmaceuticals Ltd on Wednesday said that the US health regulator has made three observations after inspecting its formulation facility in Panelav, Gujarat. “The United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals...

Read More

108 108

Dr Reddys launches allergy relief tablets in US

NEW DELHI: Drug firm Dr Reddy's Laboratories has launched levocetirizine dihydrochloride tablets, used for relieving allergies, in the US market.  In a BSE filing, Dr Reddy's Laboratories said it had "launched levocetirizine dihydrochloride tablets USP, 5 mg, an over-the-cou...

Read More

109 109

CDSCO to create forum to discuss various issues pertaining to drug regulations

NEW DELHI: India's apex drug regulator has decided to constitute a forum for its chief to meet pharma associations regularly as part of efforts to improve ease of doing business for the country's pharmaceutical industry.  Two representatives of each association will be invited ev...

Read More

110 110

Bayer Pharmaceuticals committed to India growth to push for more R&D

SINGAPORE: India continues to be one of the key markets for Bayer 1.09 % Pharmaceuticals in Asia Pacific region and it plans to continue its clinical research here, a senior company official said.  "Asia Pacific is the fastest growing region for Bayer's pharmaceuticals sales glo...

Read More

111 111

Johnson & Johnson Mylan propose ways to cut TB drugs prices in India

Johnson & Johnson and Mylan have proposed measures expected to make their multi-drug resistant tuberculosis medicines available in India at lower rates to ensure patients continue to get access to them after free supplies to the country are stopped, people familiar with the matter said. ...

Read More

112 112

Unichem Labs under regulator scanner for launching blood pressure medicines without price approval

Indian drug maker Unichem Laboratories 1.39 % has come under the National Pharmaceutical Pricing Authority’s scanner for allegedly launching six medicines for the treatment of high blood pressure years before it asked the pricing regulator to fix their retail prices. The regulator has also ...

Read More

113 113

Strides Shasun gets USFDA nod for HIV treatment drug

NEW DELHI: Strides Shasun today said it has received approval from the US health regulator for its generic Efavirenz tablet used for treatment of HIV Type-1 infected adults and adolescents.  The approval granted to the company's wholly-owned subsidiary Strides Pharma Global Pte by th...

Read More

114 114

Health sector could create jobs on massive scale: Public Health Foundation of India

Healh sector can create jobs on a massive scale, particularly at the level of frontline health workers and others, but training and skilling the job aspirants is important, Public Health Foundation of India (PHFI) President K Srinath Reddy has said.  Citing a UN report of September, 2016...

Read More

115 115

Regulator plans single window system for new drug approvals

New Delhi: In a move aimed at boosting the Make in India initiative, the Drug Controller General of India (DCGI) proposes to set up a single-window facility for innovators and start-ups seeking consents, approvals and information. DCGI plans a separate public relations (PR) office which can b...

Read More

116 116

WHO invites applications from drug companies for pre qualification of MDR TB drugs

MUMBAI: The World Health Organization on Wednesday invited drug companies to submit expression of interest to manufacture Bedaquiline and Delamanid-- the two new drugs for treating multi drug resistant Tuberculosis.  Bedaquiline, sold under the brand name Serturu by Janseen (a subsidiary...

Read More

117 117

Torrent Pharma readies UK Pound 2 billion binding offer for Sanofis European unit

Mumbai: Torrent Pharmaceuticals Ltd is readying a €2 billion (Rs16,000 crore) bid for Zentiva N.V., the generic drugs unit of France’s Sanofi, two people directly aware of the bidding process said. If Ahmedabad-based Torrent is successful, it will be the biggest outbound transactio...

Read More

118 118

Carlyle, Advent to submit bids for stake in Mankind Pharma

Mumbai: Private equity funds Carlyle Group and Advent International are poised to submit binding offers to buy a minority stake in Mankind Pharma Ltd, according to two people familiar with the matter. The bids will value the maker of Manforce condoms and pregnancy test kit PregaNews in the ra...

Read More

119 119

Cipla ties up with Roche to sell two key drugs in India

New Delhi: Drug firm Cipla Ltd and Roche Pharma India has said that they have entered an agreement under which Cipla will promote and distribute tocilizumab and Syndyma, the 2nd brand of Roche’s cancer therapy bevacizumab in India. This partnership is in line with Cipla and Roche’...

Read More

120 120

Hetero launches HIV treatment drug in India

New Delhi: Drug firm Hetero on Tuesday said it has launched generic anti-retroviral fixed-dose combination (FDC) of Emtricitabine (200mg) and Tenofovir Alafenamide (25mg) in India. The product has been approved by Drug Controller General of India (DCGI) and will be marketed and distributed un...

Read More

121 121

Lupin launches generic Axiron topical solution in US

New Delhi: Drug firm Lupin on Monday said it has launched its testosterone topical solution in the American market. The company has launched Testosterone Topical Solution, 30 mg per actuation, in the US after receiving approval from the United States Food and Drug Administration (USFDA), Lupi...

Read More

122 122

Explore new opportunities, Suresh Prabhu tells pharma industry

Union Minister of Commerce and Industry Suresh Prabhu has asked the Indian pharma industry to look at future opportunities within the country and abroad. With life expectancy going up and life-style diseases increasing, opportunities for the industry are immense as people will have to spend on me...

Read More

123 123

Brinton pharma in talks with VCs to raise up to Rs 150 crore

MUMBAI: Tata Capital Healthcare Fund-backed Brinton Pharma is looking to raise Rs 120-150 crore in a follow on round and is in talks with venture capital funds to raise cash that would primarily be used to expand the company’s geographic footprint, said three people with direct knowledge of...

Read More

124 124

Aurobindo Pharma eyes European business of Apotex

Aurobindo Pharma has expressed early stage interest in the European business of the $1.7-billion privately held Canadian drugmaker Apotex. Known for its highprofile litigations in the US against MNC pharma players, Apotex has put on the block its European operations as part of a wider consolidati...

Read More

125 125

Govt to bring major changes in Drug Pricing Control Order

The government will bring in major changes in the Drug Pricing Control Order (DPCO) and come out with a new pharma policy to implement "Namocare" across the country, Union Minister Ananth Kumar said on Thursday. Addressing the inaugural session of the India Pharma and Medical Device...

Read More

126 126

Govt may cap trade margins to control drug prices

New Delhi: The government is planning to cap how much drug retailers and wholesalers can earn on medicines they sell in an effort to arrest rising drug prices. The Department of Pharmaceuticals (DoP) has recommended an increase in trade margins, or what wholesalers and retailers earn on the sale ...

Read More

127 127

Assam for tweaking investment policy for pharma industry

Guwahati: Assam government on Sunday said it is ready to tweak its investment policies to attract the pharmaceutical sector for setting up units in the state. As there is no specific pharma policy in Assam, the government is ready to tweak the existing norms to suit the industry players of th...

Read More

128 128

Divis to spend Rs 300 crore on expansion plans in 2018

HYDERABAD: Drug firm Divis Laboratories is focussed on expanding capacities of existing plants, even as its proposed plant at Kakinada, Andhra Pradesh ran into rough weather, a senior official of the city-based drug maker said here today.  The company spent about Rs 400 crore till Decemb...

Read More

129 129

New nano technology to diagnose and treat cancer

New Delhi: Scientists have come up with a new technology that paves the way for safer and cheaper diagnosis and treatment of cancer. Under a project funded by the department of biotechnology, scientists have turned nano-particles of calcium phosphate—a bio mineral naturally found in hum...

Read More

130 130

Govt may tighten labelling norms for generic drugs

In a bid to promote low-cost generic medicines, the health ministry plans to make it mandatory for pharma firms to carry the generic names of drugs in letters that are two font sizes larger than the brand name. A notification to this effect is likely to come out soon. Once notified under the ...

Read More

131 131

Pharma firms to tap M&A opportunities to gain scale, tide over challenges

Mumbai: Leading Indian pharmaceutical companies, struggling to cope with a slowdown in growth and reduced profitability over the last couple of years, are expected to try and tap inorganic opportunities globally in order to increase scale of business and rise above challenges. The focus of la...

Read More

132 132

Diabetes drug major USV eyes niche therapies abroad, targets Rs 50 bn sales

USV, the country's largest manufacturer of oral anti-diabetes drugs, is stepping up focus on biosimilars and niche low-competition products in Europe and the US, as it looks for new growth opportunities to achieve Rs 50 billion (Rs 5,000 crore) revenue in the next five years. It would have an...

Read More

133 133

WHO awards prequalification to Bharat Bios Rotavirus vaccine

India's vaccine maker Bharat Biotech has announced receiving prequalification from the World Health Organisation (WHO) for its rotavirus vaccine Rotavac, considered the developing world's first rotavirus vaccine.  The vaccine to prevent infant deaths and hospitalisations due to r...

Read More

134 134

Indian pharma cos get record 300 USFDA generic drug nods

Domestic pharma companies received more than 300 approvals in 2017 to launch generic drugs in the US, which is an all-time high. The clearances came despite regulatory pressure from the US Food and Drug Administration (FDA), and unprecedented warning letters issued to the pharma companies' fa...

Read More

135 135

Carlyle Group leads race for 15 per cent in Mankind Pharmaceuticals

MUMBAI: Carlyle Group is leading the race to invest as much as $500 million for a 15% stake in Mankind Pharmaceuticals in what could become one of the largest private equity transactions in the pharma space. The transaction, if it happens, will value the Delhi-based company at about $3.3 billion....

Read More

136 136

Pharma regulator NPPA warns industry of stricter price action

The National Pharmaceutical Pricing Authority (NPPA) has warned the pharmaceutical industry of stricter price regulation, a move which could weaken sales growth of the sector. “The pricing regime will be strict than what it is so far. The government is answerable to the people,” N...

Read More

137 137

CMFRI to expand research to tap pharma prospects of marine life

Kochi: The Central Marine Fisheries Research Institute (CMRI) here has decided to expand research network to tap pharmaceutical prospects of marine organisms, its top scientist said today. CMFRI Director Dr A Gopalakrishnan said there was a growing demand for new bioactive compounds of marine...

Read More

138 138

Indian pharma majors are rushing to ‘Make in America’

US President Donald Trump's 'Make in America' pledge may have spooked many, but Indian pharmaceutical companies are optimistic.  Several Indian drugmakers that have large operations in the US are now pushing to acquire assets there by either investing in greenfield manufactur...

Read More

139 139

Torrent Pharma buys US firm Bio Pharm

Torrent Pharmaceuticals has acquired Bio-Pharm, a generic and overthe-counter drugmaker based in Levittown, Pennsylvania, for an undisclosed sum.  "This acquisition is an important step for increasing Torrent's presence in the United States, is consistent with our strategy of do...

Read More

140 140

Global digital health venture capital funding up 42 per cent at $7.2 billion

NEW DELHI: Venture capital (VC) funding, via private equity as well as corporate, jumped 42 per cent to a record USD 7.2 billion in the digital health sector globally last year through 778 deals, says a report.  According to Mercom Capital Group, the sector saw USD 5.1 billion in 622 dea...

Read More

141 141

Panacea Biotec partners Serum Institute for hexavalent vaccine

NEW DELHI: Panacea Biotec has signed two long-term agreements with Serum Institute of India (SII) and its wholly-owned subsidiary to manufacture and sell a type of hexavalent vaccine.  The vaccine is a combination of six antigens to protect against six dreaded diseases - Diphtheria, Teta...

Read More

142 142

Why healthcare ideas need profitability, Curraes Patni and Mahipal explain

Currae HealthTech Fund, a Rs 1-billion one led by Apoorva Patni, is an investment house keen to build a footprint in the health technology sector. Ajay Mahipal, investment head of Currae, joins Patni to discuss why the technology needs to be profitable to sustain and the challenges it faces. Edit...

Read More

143 143

NPPA fixes retail price of 30 drug formulations

NEW DELHI: Drug price regulator NPPA today said it has fixed the retail price for 30 drug formulations, including those used for treatment of diabetes, bacterial infections and high blood pressure.  The National Pharmaceutical pricing Authority (NPPA) has also revised the prices of three...

Read More

144 144

Long wait at govt facility, Get free surgery at pvt hospital

New Delhi: Lieutenant governor Anil Baijal on Tuesday approved the government's scheme 'quality health for all'. It pertains to providing patients specified, high-end diagnostic (radiological) tests and surgeries for free at private hospitals, in case of delay in government facilities...

Read More

145 145

JB Chemicals & Pharma s Gujarat facilities get European nod

NEW DELHI: JB Chemicals & Pharmaceuticals today said the Medicines Authority of Malta has granted European GMP approval to its manufacturing facilities located at Panoli, in Gujarat.  "JB Chemicals & Pharmaceuticals is pleased to announce receipt of European GMP approval for...

Read More

146 146

Tata Trusts launches Impact Lab for public health

Tata Trusts today said it has set up an 'Impact Lab' at IIT Delhi in partnership with health innovation player PATH for healthcare solutions in areas such as maternal and child health, nutrition and diagnostics for chronic and infectious diseases, among others.  The collaboration...

Read More

147 147

Piramal Enterprises explores re entry into Indian formulations business

MUMBAI: Piramal Enterprises is evaluating a return to the domestic formulation market after a non-compete agreement with Abbott expires this year, said people familiar with the plan.  The company is looking at introducing respiratory and central nervous system formulations in India, the ...

Read More

148 148

Regulator weighs inspection of drug making facilities in US

NEW DELHI: India's drug regulator is looking to inspect US pharmaceutical facilities making "critical" medicines so that only high quality products are imported from them, three government officials have said.  After taking action against drug makers in China for qual...

Read More

149 149

VPS Healthcare ventures into medical coding

KOCHI: VPS Healthcare, the healthcare conglomerate with a chain of hospitals in india and the Gulf, has ventured into medical coding by launching a new group company named Dynamed Healthcare Solutions at Infopark phase-2 in Kochi.  Medical coding is the transformation of healthcare diagn...

Read More

150 150

Lupin forays into OTC segment; eyes Rs300 crore turnover in 5 years

New Delhi: Drug major Lupin on Monday said it has forayed into over-the-counter (OTC) segment in the country with plans to touch Rs300 crore turnover in the vertical over the next five years. The Mumbai-based firm has introduced its legacy product ‘Softovac’ across the country as ...

Read More

151 151

Pharma M&A: buying its way back to growth

Why Indian pharmaceutical companies are keen on global acquisitions is not hard to fathom. A Crisil report estimates the sector’s revenue to increase by 9% per annum till fiscal 2020, with overseas revenue growing by a mere 1% in 2018 and then improving. But for domestic growth in the r...

Read More

152 152

Domestic medical device makers seek hike in basic custom duty

NEW DELHI: The government needs to increase the basic customs duty on medical devices in the range of 5-15 per cent to promote domestic manufacturing, Association of Indian Medical Device Industry (AiMeD) said today.  The current slab is 0-7.5 per cent, it said.  "The governm...

Read More

153 153

Indian pharma majors weigh bids for Sanofi’s $2 billion European generics business

MUMBAI: Homegrown Aurobindo, Zydus Cadila, Torrent Pharma and Intas have expressed preliminary interest in buying the European generics business of Paris-headquartered pharma giant Sanofi as frenzied dealmaking continues in Big Pharma the world over in the new year.  The portfolio of acu...

Read More

154 154

Eyeing over 80 percent sales from US, India, Europe by 2021 Glenmark

NEW DELHI: Glenmark Pharmaceuticals today said it expects the US, Indian and European markets, along with active pharmaceutical ingredient (API) segment, to contribute over 80 per cent to its sales by 2021.  As part of its medium term strategy, the company is also looking at increasing p...

Read More

155 155

Drug regulator teaming up to re inspect manufacturing plants of pharma cos in next three weeks

India's drug regulator is gearing up to re-inspect manufacturing plants of several pharmaceutical companies across the country to ensure they have taken measures to improve the quality of medicines sold here and exported to other markets. The re-inspections, which will see the centre and stat...

Read More

156 156

Hilleman Labs to partner future vaccine manufacturing hub

NEW DELHI: Hilleman Laboratories, a joint- venture between pharma major MSD and Wellcome Trust, today said it has partnered a new future vaccine manufacturing hub led by Imperial College, London.  UK Department for Health has granted GBP 10 million funding for the hub that will be manage...

Read More

157 157

Glenmark launches biosimilar Adalimumab in India

MUMBAI: Mumbai based Glenmark Pharmaceuticals on Wednesday said it has launched the biosimilar Adalimumab under a licensing agreement with Cadila Healthcare Ltd. Adalimumab is used in the treatment of Plaque Psoriasis and Rheumatoid Arthritis is the spin off version of US drug maker AbbVie which ...

Read More

158 158

Dip in pharma exports due to shifting of manufacturing bases, market consolidation Government

NEW DELHI: Shifting of manufacturing bases to overseas markets by certain domestic companies and absence of blockbuster drugs going off-patent are some of reasons for dip in India's pharmaceutical exports, Parliament was informed today.  In 2016-17, the exports decreased by 0.43 per ...

Read More

159 159

Bharat Biotech s typhoid vaccine gets WHO pre qualification

HYDERABAD: Bharat Biotech today said its Typbar TCV or the Typhoid Conjugate Vaccine against typhoid fever, has received pre-qualification from the World Health Organisation (WHO).  This enables the procurement and supplies of this vaccine to UNICEF, Pan-American Health Organisation (PAH...

Read More

160 160

NPPA fixes retail prices of 14 formulations

Drug price regulator NPPA has fixed retail prices of 14 formulations, including of those used in treatment of high cholesterol and high blood pressure.  In a notification on its website, the National Pharmaceutical Pricing Authority (NPPA) said the capped retail prices of the 14 formulat...

Read More

161 161

Hetero launches HumiraTM biosimilar in India

Indian drug maker Hetero has launched a biosimilar of AbbVie's 'HumiraTM' (adalimumab) for the treatment of rheumatoid arthritis and other auto immune disorders in India, the company stated in a release. This Hetero's fourth biosimilar drug, it added.  The product will be...

Read More

162 162

Indian pharma will continue to stare at single digit growth ICRA

MUMBAI: The growth trajectory for Indian pharmaceutical industry is likely to be moderate on back of slowing growth from US given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion in low-to--mid-teens, generic adoption reaching...

Read More

163 163

Vivimed Labs gets additional $7.5 million funding from OrbiMed Asia

NEW DELHI: Drug firm Vivimed LabsBSE -0.38 % today said it has received additional investment of USD 7.5 million (over Rs 47 crore) from healthcare investment firm OrbiMed Asia in its subsidiary Vivimed Labs (Mascarene).  The company had earlier received USD 42.5 million from OrbiMed Asi...

Read More

164 164

Apax Partners Carlyle front runners for Mankind Pharma stake sale

Delhi based Mankind Pharma, one of India's top pharmaceutical companies and maker of leading brands like Manforce condoms, PregaNews & Unwanted 72 is in advanced stages of a mega fund raising round with two private equity players emerging as front-runners, multiple sources familiar with o...

Read More

165 165

Zydus Pharmaceuticals gets USFDA nod for OCD treatment drug

NEW DELHI: Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market Clomipramine Hydrochloride capsules, used to treat obsessive compulsive disorder (OCD).  The company has received final approval from the US Food and Drug Administration (USFDA) ...

Read More

166 166

Pharma companies revenues seen clipping at 9 percent over next 3 yrs

MUMBAI: Robust domestic demand and rising need for complex products in the West will help domestic pharma players log in a 9 per cent revenue growth with healthy cash flows over the next three years, offsetting headwinds in exports and rising competition, says a report.  "Revenue of...

Read More

167 167

Governments medicare drive pinches pharma private hospitals in 2017

NEW DELHI: Indian pharmaceutical and healthcare sectors will step into the new year with lingering bitter after-effects of proactive measures of the government, which pulled out all the stops in 2017 for affordable medicare in the country.  While the government's directive to doctors...

Read More

168 168

USFDA accepts Sun Pharma arms ophthalmic drug application

NEW DELHI: The US health regulator has accepted a new drug application (NDA) for an ophthalmic solution filed by Sun Pharma wholly-owned subsidiary, the drugmaker said today.  "The US Food and Drug Administration (USFDA) has accepted a new drug application (NDA), filed by its wholly...

Read More

169 169

Dr.Reddys launches anti cancer injection in US market

HYDERABAD: Dr.Reddy's Laboratories today said it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection, in the United States market.  The drug, which is used to treat certain types of cancer, wa...

Read More

170 170

Aurobindo Pharma gets USFDA nod for Fondaparinux Sodium injection

NEW DELHI: Aurobindo Pharma  today said it has received final approval from the US health regulator to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent deep vein thrombosis.  The approval by US Food & Drug Administration (USFDA) is for ...

Read More

171 171

Code for pharma marketing practices may be enforced soon

New Delhi: A revised final draft of a code regulating promotional practices in the pharmaceuticals industry, such as offering gifts to medical professionals, has been sent to the law ministry for vetting, two people familiar with the matter said, indicating that the code could soon be enforced. ...

Read More

172 172

Israel's Super Pharm in talks to buy Teva plant

Israel’s largest pharmacy chain Super-Pharm (Israel) is in talks to acquire Teva Pharmaceutical Industries’ plant in the coastal city of Ashdod, a source familiar with the matter said on Sunday, confirming media reports.  Super-Pharm would pay 60-80 million shekels ($17-23 mi...

Read More

173 173

Domestic firms volunteer to drop syringe, needle prices over 50 percent

In a move that could bring down the prices of several Indian syringe and needle brands by over 50%, a lobby group of domestic manufacturers has decided to voluntarily reduce the maximum retail prices of these products. The move comes amid rising speculation and debate over whether prices of more ...

Read More

174 174

Local stent companies catch fancy of PE players

NEW DELHI / MUMBAI: One company's misery is another's fortune. This seems to be the case with stent manufacturers, too.  As multinational stent makers ponder their prospects in India after price controls introduced this year, their local rivals, which had been struggling to make ...

Read More

175 175

India developing bulk drugs to reduce import dependence

India is in the process of developing a range of bulk drugs to reduce import dependence, especially from China, a top government official said today.  Although a large quantity of bulk drugs is imported from China, India has enough capacity for producing active pharmaceutical ingredients...

Read More

176 176

Strides bags majority stake in South Africas Trinity

Drug firm Strides Shasun today said its subsidiary has entered into an agreement to acquire controlling stake in South Africa's Trinity.  "Strides Pharma Asia Pte, Singapore, a wholly-owned subsidiary of Strides Shasun has entered into definitive agreements with Trinity Pharma P...

Read More

177 177

Morepen Labs gets USFDA nod for asthma drug

Morepen Laboratories today said the US health regulator has given approval to Montelukast Sodium, used in managing asthma symptoms and seasonal allergies, for sale in the US market.  "The US Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug/API manufac...

Read More

178 178

Lincoln Pharma gets patent for antimalarial drug

Lincoln Pharmaceuticals has been awarded a patent for anti-malarial drug in India, the company said today.  The patent has been awarded by the Indian government for an Arteether injection to treat malaria, according to a BSE filing.  The drug is painless and gives faster relief ...

Read More

179 179

Biocon to invest in Uttar Pradesh health sector

BENGALURU/LUCKNOW: Biopharma company Biocon's CEO Kiran Mazumdar-Shaw said in Bangalore on Monday that she would invest in the healthcare centres of Uttar Pradesh and encourage entrepreneurs in the biotech space, especially the startups, to work in the state.  During a road show orga...

Read More

180 180

Drug makers can now expect more regular checkups from USFDA

MUMBAI: Audits of Indian drug manufacturing facilities by the Food and Drug Administration are set to rise sharply after October's Mutual Recognition Agreement between the US regulator and eight European Union member states.  The pact, seen as an unprecedented move, includes Sweden, ...

Read More

181 181

Aurobindo, Dr Reddy's Laboratories frontrunners to buy out bankrupt Orchid Pharma

MUMBAI: Indian drug companies Aurobindo Pharma Ltd. and Dr Reddy's Laboratories Ltd. are emerging as the frontrunners to buy out bankrupt Orchid Pharma Ltd. as they seek to expand their capacities.  A key player in injectibles and active pharmaceutical ingredients (API) in its heyday...

Read More

182 182

Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

NEW DELHI: The Supreme Court has asked the country's technical advisory body on drugs to decide on the fate of more than 300 combination medicines banned by the government between March 2016 and June 2017. The order is a potential relief to drug makers who have argued that the government did ...

Read More

183 183

Torrent Pharma completes acquisition of Unichem Laboratories Ltd

Torrent Pharmaceuticals Limited on Thursday announced that it has completed acquisition of branded business of Unichem Laboratories Limited for India and Nepal, including its Sikkim manufacturing facility, on a going concern basis by way of slump sale. This transaction was in pursuance of the def...

Read More

184 184

Government to cap profits made by hospitals to stop overcharging

NEW DELHI: The Delhi government has decided to cap the profits made by hospitals while selling medicines or consumables to patients. The big change is that the maximum retail price (MRP) is not going to be the criterion that will decide the profit margin. Delhi health minister Satyendar Jain decl...

Read More

185 185

PerkinElmer may invest over $100 million in India by 2022

NEW DELHI: American health technology firm PerkinElmer may invest over $100 million in tie-ups with the government and acquisitions mainly in reproductive health by 2022. The company, which acquired one of India's largest providers of in-vitro diagnostic products earlier this year, is in talk...

Read More

186 186

JB Chemicals & Pharma gets USFDA nod for hypertension tablets

NEW DELHI: JB Chemicals & Pharmaceuticals has received US health regulator's nod for Atenolol tablets, used in treatment of high blood pressure.  "The United States Food and Drug Administration (USFDA) has approved the company's supplementary Abbreviated New Drug Applica...

Read More

187 187

Novo Nordisk India and Torrent Pharma expand their insulin manufacturing facility

Nova Nordisk India and Torrent Pharmaceuticals on Monday announced expansion of their insulin manufacturing facility at the latter's Indrad factory, 40 kms from state capital Gandhinagar. Currently reaching out to 3mn patients, the expansion would enable Novo Nordisk to tap 5 mn patients, Mel...

Read More

188 188

Suven gets product patents from India, US

NEW DELHI: Suven Life Sciences has secured a product patent each from India and the US for treatment of disorders associated with neurodegenerative diseases.  These patents are valid through 2029 and 2033 respectively, the company said in a BSE filing.  "We are pleased by t...

Read More

189 189

Rhizen receives USFDA fast track designation for cancer drug

Drug firm Alembic Pharmaceuticals today said the US health regulator has granted fast track designation to its associate company Rhizen Pharmaceuticals SA's RP6530 (tenalisib), used in treatment of cancer. "The US Food and Drug Administration (USFDA) has granted Fast Track Designatio...

Read More

190 190

E Pharma medicines to be more affordable

Hyderabad: With 50 online pharmacies now operational in India, a review by the Drugs Controller General of India contends that e-pharmacies will be the game-changers as they will make medicines more affordable to consumers. Tushar Kumar, founder of online pharmacy Med-life, said, “Online ph...

Read More

191 191

Mylan wants to capture chronic Hep B market

NEW DELHI: US drugmaker Mylan hopes to capture a “major” share of the Rs 140-crore market for chronic Hepatitis B with the launch of its once-daily tablet for this infection in adults. The drug will have a maximum retail price of Rs 1,900 for a pack of 30 tablets, said the company&rsq...

Read More

192 192

Serum Institute to launch 4 vaccines, enter US, Europe markets

NEW DELHI: Homegrown global vaccines major Serum Institute of India plans to launch at least four products and enter European and US markets in the next three to four years as it seeks to retain number one position.  The company sells its products in 147 countries and is the largest vacc...

Read More

193 193

This company is ready to flood the US with cheap HIV drugs

Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the US market with the low-cost copycat medicines.  US patents on key components for some important HIV therap...

Read More

194 194

New Zealand billionaire backs Indiabulls Pharma

Billionaire investor-turned-philanthropist Richard Chandler has picked up a stake of about 9% in the one-year old Indiabulls Pharmaceuticals for Rs 155 crore, valuing the company at about Rs 1,800 crore. Set up in mid-2016, it’s a privately held company that was wholly owned by Indiabulls g...

Read More

195 195

New expert committee to consult on drug pricing, new drug launches

NEW DELHI: The ministry of chemicals and fertilizers' pharmaceuticals department has decided to constitute a new expert committee to consult the country's drug pricing regulator on all technical issues related to pricing and new drug launches. At the same time, the regulator is not expect...

Read More

196 196

Biosimilar drug by Mylan, Biocon gets USFDA approval

MUMBAI: A decade-long partnership of US drug maker Mylan and Bengaluru-based BioconBSE 9.38 % saw the light at the end of tunnel as the US FDA granted marketing approval to its biosimilar drug Trastuzumab last Friday night. This ends the speculation over the drug’s launch.  Trastuz...

Read More

197 197

Glenmark Pharma gets approval for inhaler product in Nordic countries

Glenmark Pharmaceuticals Europe Ltd on Friday said it has received approval for an inhaled respiratory product in Nordic countries, including Sweden, Denmark, Norway, Finland and Iceland. The company "has successfully closed the decentralised registration procedure for generic Seretide A...

Read More

198 198

Piramal acquires Digeplex from Shreya Lifesciences

MUMBAI: Piramal Enterprises today acquired the Digeplex and the associated brands from Shreya Lifesciences for an undisclosed sum to expand its consumer products business.  The acquisition will help the Ajay Pirmal-led company expand its gastro-intestinal product portfolio. "We ...

Read More

199 199

Government needs proactive approach to boost pharma sector: Industry

MUMBAI: Union and state governments needs to develop a proactive approach towards building better quality compliance and become a facilitator of funds and platforms, leaving the mechanism of delivery to the private sector to help the pharma sector grow faster, according to industry experts. ...

Read More

200 200

Nigeria new attraction for Indian pharma firms

ACCRA: As Indian pharma firms look to increase their footprints in Africa, Nigeria seems to be offering opportunities, as its pharmaceutical market is likely to grow to $3.6 billion by 2026, according to a study by international consulting group McKinsey.  "The Nigerian pharma marke...

Read More

201 201

How India can make cheap and quality medicines available to all

In the mid-1990s, India identified availability, accessibility and affordability of medicines as the major weaknesses in its drive for quality and affordable healthcare for all. More than a decade passed before the UPA government started the Jan Aushadhi Scheme (JAS) in 2008 to counter high price...

Read More

202 202

India likely to get dengue vaccine by end of 2019

New Delhi: India is likely to get a vaccination for Dengue by the end of 2019. Pharmaceutical giant Panacea Biotec has secured permissions to conduct a clinical trial in the country after the Drug Controller General of India permitted it to test the viability, as per media reports. The cl...

Read More

203 203

Founded by 2 Gujaratis, US drug major Amneal eyes speciality biz in India

Two Indian-American brothers hailing from Gujarat, Chirag and Chintu Patel, have built a $1.8-billion drug major Amneal Pharmaceuticals in the US from scratch in around a decade and a half. After its recent merger with Impax Laboratories last month, the combined entity, with revenues of $1.75-1.8...

Read More

204 204

Hyderabad entrepreneur acquires medical informatics firm Pulsus

Hyderabad-based serial entrepreneur Dr Srinubabu who runs Omics International, has acquired Canada-based scientific medical informatics Pulsus Group, foraying into scientific, medical informatics market worldwide for an undisclosed amount. He also announced Pulsus will expand in India with two ne...

Read More

205 205

Pharma firms tide over GST impact

AHMEDABAD: Normalcy seems to have been restored in the domestic pharmaceutical market with improvement in drug inventory of stockists. This is evident from an uptick in domestic market sales of top pharmaceutical companies in the state such as Cadila Healthcare Limited, Torrent Pharmaceuticals Li...

Read More

206 206

Eris Life to acquire Strides India business for Rs 500 crore

MUMBAI: Bengaluru-based drug maker Strides Shasun has agreed to sell its domestic branded formulations business to Ahmedabad-based Eris Lifesciences for Rs 500 crore, joining a select league of Indian pharmaceuticals firms exiting domestic market to focus on more lucrative international business....

Read More

207 207

Glenmark Pharmaceuticals launches nicotine gum Kwitz

Glenmark Pharmaceuticals today said it has launched nicotine replacement therapy product Kwitz that helps smokers quit smoking.  Kwitz nicotine gum will be available in two variants of 2 mg as an OTC product 4mg as prescription product, the company said in a statement.  While Kw...

Read More

208 208

DRL launches anti cancer drug in US market

Dr. Reddy s Laboratories Ltd today announced today that it has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (clofarabine) Injection in the United States market, following the approval from the US Food and Drug Administration (USFDA).  According to a ...

Read More

209 209

OmniActive Health eyes more takeovers, to invest Rs 150 cr

OmniActive Health Technologies, a leading nutraceutical company, is looking at more strategic acquisitions in domestic and foreign markets and has drawn up capital expenditure plans of around Rs 150 crore in the next three years.  Building on an M&A (mergers and acquisitions) strateg...

Read More

210 210

Zydus gets regulatory nod to market Lipaglyn in Mexico

Drug firm Zydus today said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for treatment of dyslipidemia in patients with diabetes.  The company has been granted marketing approval from the Mexican regulatory authority COFEP...

Read More

211 211

Price controls will devalue healthcare system in India, Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw, chairman and managing director of Biocon has called on the Centre to be careful in controlling prices of drugs and equipment saying that this could potentially impact the quality of healthcare in India. "I think there is an affordability price-point which people need...

Read More

212 212

Morepen inks pact with Vésale Pharma to boost presence in Rs 1000 crore probiotics market

NEW DELHI: Indian pharmaceutical firm Morepen LaboratoriesBSE 1.40 % Ltd, listed on the Bombay Stock Exchange, has inked an exclusive agreement to market and distribute Belgian probiotics player Vesale Pharma International's major brands in the gastroenterology segment—a deal it hopes w...

Read More

213 213

Torrent Pharma to buy Unichem Labs' India business for $558 million

Torrent Pharmaceuticals said on Friday it would buy more than 120 brands of Unichem Laboratories in India and Nepal and its manufacturing plant at Sikkim.  The deal, valued at 36 billion rupees ($558 million), will be funded by internal accruals and bank borrowing, the drugmaker said in ...

Read More

214 214

New dengue virus confirmed in India

PUNE: A new dengue virus has been confirmed for the first time in the country.  Scientists at Pune-based National Institute of Virology (NIV), who spotted it and had been tracking it, said the new virus of an Asian genotype (genetic structure) was a concern as it was associated with seve...

Read More

215 215

Serum Institute to launch new vaccines; foray in Europe, US markets by 2020

Serum Institute chief executive officer Adar Poonawala has called for policy reforms to boost competitiveness as the company plans to launch new vaccines and make a foray in Europe and US markets by 2020. The 50-year-old Pune based company is the world's largest producer of vaccines by vo...

Read More

216 216

Glenmark launches oral drug for Psoriasis treatment in India

NEW DELHI: Glenmark Pharmaceuticals today said it has launched Apremilast, the first advanced oral systemic treatment for Psoriasis in India.  Apremilast, which is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of moderate to severe Psoriasis, will revolutionise the t...

Read More

217 217

The much awaited 8th edition of Pharmac India is all set to take place in Ahmedabad

The much awaited 8th edition of Pharmac India is all set to enthrall visitors and delegates from all over the world and is scheduled to take place from 7th to 9th November 2017. Gujarat University Exhibition and Convention center will once again host the three days industry extravagance. The 8th ...

Read More

218 218

82 percent people of Delhi, Mumbai prone to heart disease due to stress: Survey

Going against the popular belief that improper diet and lack of exercise were responsible for heart disease, the survey conducted by ICICI Lombard reveals that stress is a prime cause of cardiac conditions. The survey also highlights that 82 per cent people in Delhi and Mumbai are more prone to c...

Read More

219 219

Lupin US arm takes over Symbiomix Therapeutics

MUMBAI: Lupin on Wednesday said it has acquired Symbiomix Therapeutics, a US-based company specialising in drugs for gynaecologic infections, for cash considerations of $150 million, or about Rs 980 crore. The acquisition, made through the firm’s US subsidiary Lupin Pharmaceuticals, involve...

Read More

220 220

Piramal Pharma announces expansion of API manufacturing facilities

Piramal Pharma Solutions (PPS), a contract development and manufacturing organisation (CDMO) announced investments of USD 55 million across its sites in North America and Asia to expand its API manufacturing capabilities and capacities.  A part of USD 55 million investment will go into n...

Read More

221 221

Drug makers may have to declare ex factory price on medicine packs

NEW DELHI: With a view to bringing in transparency in drug pricing, the government plans to make it mandatory for pharmaceutical companies to disclose MRP as well as `ex-factory' price on the packs of medicines.  The proposal has perturbed the pharmaceutical companies as it will put ...

Read More

222 222

Intas launches chemotherapy drug at affordable price

Ahmedabad-based Intas Pharmaceuticals has launched the cancer drug Bevacizumab at prices 60 per cent less than the currently available options.  On Wednesday, the company announced that its Bevacizumab therapy would cost Rs 39,995 for the dose strength of 400 mg variant, which makes it 6...

Read More

223 223

Eris Lifesciences acquires UTH Healthcare for Rs 12.85 crore

Ahmedabad based Eris Lifesciences, that has clocked a 21.7 per cent compounded annual growth rate (CAGR) from FY13 to FY17, has acquired nutraceuticals company UTH Healthcare Ltd. in an all cash deal. Eris has acquired 100 per cent shareholding of UTH for Rs 12.85 crore.  This is the com...

Read More

224 224

Gland Pharma to leverage Fosun’s strengths for growth

MUMBAI: Gland Pharma aims to double its injectables capacity in the next two to three years before going public, a top company executive said a day after Chinese drugmaker Fosun Pharma said it acquired 74 per cent stake in the Hyderabad-based firm. Gland Pharma will also increase its product port...

Read More

225 225

After Gland, Chinese pharma giant Fosun eyes API maker Symbiotec

MUMBAI: Weeks after Chinese pharmaceutical giant Fosun tweaked its acquisition of Hyderabad-based Gland Pharma for $1 billion (Rs 6,500 crore), it is out shopping again to further strengthen its India presence.  Shanghai-based Fosun Pharmaceutical is in talks to acquire the manufacturing...

Read More

226 226

Pharma companies lag in digital journey against global counterparts

MUMBAI: Indian pharmaceutical companies lag behind in their digital journey as compared to their global counterparts, according to a industry report.  Global advisory firm, EY today launched its latest report - 'Reinventing pharma sales and marketing through digital in India', co...

Read More

227 227

NPPA caps prices of 39 drugs used for treating cancer, malaria

Drug price regulator NPPA on Wednesday said it has fixed the ceiling price for 39 more drug formulations, including those used for the treatment of cancer, tuberculosis, malaria and hepatitis B among others. The National Pharmaceutical Pricing Authority (NPPA) said while the ceiling price of ...

Read More

228 228

Speciality segment to be a key growth driver for Sun Pharma

Drug major Sun Pharmaceutical Industries today said it has identified speciality segment as one of the key drivers for growth going forward.  The global pharmaceutical landscape is rapidly changing. There are opportunities as well as challenges. This mandates identifying new and profitab...

Read More

229 229

Currency fluctuation in semi regulated markets to hit Indian pharma: Fitch

MUMBAI: Indian pharma exporters road to recovery might still take time as weak economic and political conditions in Africa and currency volatility in Latin America (LATAM) are likely to weigh on the consumption of pharmaceutical formulations according to India Ratings and Research (Ind-Ra), a rat...

Read More

230 230

Assam to set up technology incubation centre at Guwahati Biotech Park

GUWAHATI: The Assam government has started a process to set up a technology incubation centre at Guwahati Biotech Park, seeking to promote new businesses in biotechnology and allied areas.  The initiative will facilitate faster penetration of biotech industry and accelerate research &...

Read More

231 231

Fosun Pharma to buy 74 percent stake in Gland for USD1.09 billion

Shanghai Fosun Pharmaceutical Group has agreed to cut the size of the stake it would buy in Hyderabad-based injectable maker Gland Pharma to 74 per cent in a revised $1.09-billion (around Rs 6,900 cr) deal after its earlier proposal to acquire 86 per cent met approval roadblock.  In a st...

Read More

232 232

Laurus Labs gets USFDA nod for Visakhapatnam unit

Hyderabad-based Laurus Labs Limited has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its formulations and active pharmaceutical ingredient (API) manufacturing plant, Unit 2 located in Visakhapatnam. The inspection was completed in May, 2017. ...

Read More

233 233

Cadila Healthcare receives USFDA nod for two drugs

Drug firm Zydus Cadila on Friday said it has received approvals from the US health regulator for its Modafinil and Solifenacin Succinate tablets, and the drugs will be manufactured at Ahmedabad facility. The company has received final approval from the United States Food and Drug Administrati...

Read More

234 234

After GST jitters, pharma market back on growth track in August

After slipping into the negative in July, thanks to a temporary slowdown in drug sales caused by the transition to the Goods and Services Tax (GST), the Indian pharmaceutical market (IPM) was back on track in August, registering 2.4 per cent year-on-year (YoY) growth during the month.  D...

Read More

235 235

MSD launches blockbuster cancer drug Keytruda in India

NEW DELHI: US biopharmaceutical giant Merck, Sharpe and Dohme (MSD) has launched its blockbuster cancer drug ‘Keytruda’ (pembrolizumab) in India around a year after it first received approvals to market it, said persons aware of the development. The drug has so far only been approved ...

Read More

236 236

Patented drug launches help MNCs score over Indian peers

MUMBAI: At a time when the pharmaceuticals industry is facing the heat with price cuts and regulatory issues in the country, multinational companies are growing faster than their domestic peers due to better product mix, says a study.  While Indian companies still control almost 80% of t...

Read More

237 237

Biocon aspiring for USD1 billion revenues by FY 2019

NEW DELHI: Biocon is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services as it targets $1 billion revenue by the next fiscal.  The Bengaluru-based firm, which has been chasing the target since 2011, has identified these vertica...

Read More

238 238

Cadila's Moraiya plant successfully completes USFDA inspection

Drug firm Cadila Healthcare on Thursday said the US health regulator has issued no observations after completion of inspection of its Moraiya plant in Gujarat. The United States Food and Drug Administration (USFDA) has inspected the company's Moraiya facility from August 31-September 7, 2...

Read More

239 239

Biocon's Malaysian arm gets EU certification for insulin facility

Biopharmaceutical firm Biocon today said its Malaysian arm Biocon Sdn Bhd has received EU GMP compliance certificate from the Health Products Regulatory Authority of Ireland for its insulin manufacturing facility. "Biocon's subsidiary in Malaysia, Biocon Sdn Bhd, has been issued a ce...

Read More

240 240

Merck KGaA may sell consumer health business

NEW DELHI: Merck KGaA is looking to sell its $1-billion global consumer health business, including that in India, in a move that the German drugmaker said will be an important step in executing its science and technology-focussed strategy.  The company is preparing for “strategic o...

Read More

241 241

GlaxoSmithKline sets up first team for acquisitions in 93 years

GlaxoSmithKline (GSK) Pharmaceuticals is scouting for acquisitions in the domestic market for the first time since it started its operations in the country 93 years ago.  The change in strategy comes at a time when the government’ increasing price control over branded generic medic...

Read More

242 242

Arrow Pharma acquires Australian operations of Amneal Pharma

NEW DELHI: Drug firm Strides Shasun today said its arm Arrow Pharmaceuticals has acquired Australian operations of Amneal Pharmaceuticals for a total consideration of AUD 17 million (over Rs 85 crore).  The acquisition would accelerate Arrow's market reach and will help in attaining ...

Read More

243 243

Drug distributors push for cap on margins

Distributors present in the pharmaceutical policy meet, held in New Delhi on Wednesday, agreed to the government’s idea to cap trade margins to make drugs affordable. Suresh Ranka, a representative from the  All India Chemists and Distributors Federation, said that for branded drug...

Read More

244 244

USFDA hikes fee for processing ANDA by USD 1 lakh for FY18

HYDERABAD: Citing high workload, the US Food and Drug Administration (USFDA) has increased fee for processing Abbreviated New Drug Application (ANDA) by over USD 1 lakh to USD 1.71 lakh for the fiscal year 2018. The hike was made under Generic Drug User Fee Amendments of 2017 (GDUFA II). The ...

Read More

245 245

The State of Pharmaceutical Industry in India, An Overview.

New Delhi: Indian pharmaceutical industry, with current market size of $27.57 billion (last reported in 2016) is expected to reach a mark of $55 billion by 2020 at a CAGR of 15.92%, according to a report by the Indian Brand Equity Foundation (IBEF). In the next three years, India is projected to ...

Read More

246 246

Health ministry objects to pharma policy proposals

New Delhi: The health ministry has objected to a proposal that will end its role in selecting drugs to be brought under price control and cede control of regulator Central Drugs Standard Control Organization (CDSCO) to the department of pharmaceuticals under the fertilizer and chemicals ministry....

Read More

247 247

Gilead to buy Kite Pharma for promising cancer therapies in USD12 bn deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions. Gilead will pay $180 per share in an all-cash deal, representing a 29.4 percent premium over...

Read More

248 248

Japanese drug maker Eisai to expand Vizag plant

Eisai Pharmaceuticals plans to expand its manufacturing plant in Visakhapatnam and set up an innovation centre to support its new drug development programmes. The Japanese drug maker sells cancer and central nervous disorder drugs in India. It has a manufacturing unit in Visakhapatnam (Vizag)...

Read More

249 249

India's proposed pharma marketing rules hit legal roadblock

MUMBAI: India's plan to bring in marketing rules to curb unethical promotional practices in the country's drug industry faces an indefinite delay after it hit a legal roadblock, marking a setback for public health groups.  The country's law ministry has rejected draft marketi...

Read More

250 250

India grants Pfizer patent for blockbuster brand Prevenar 13

NEW DELHI: India has granted US drug giant Pfizer a patent for its blockbuster Prevenar 13, a vaccine that helps prevent cases of pneumonia, one of the leading causes of deaths of children under five years of age. The approval comes more than a decade after the company applied for the patent in t...

Read More

251 251

ICMR partners with IVI, invests Rs 3.20 crore for vaccine development in India

NEW DELHI: The Indian Council of Medical Research (ICMR) has entered into an agreement to collaborate on vaccine research and development with international vaccine development organisation International Vaccine Institute (IVI). Through this partnership, India will commit $5,00,000 (Rs 3.20 crore...

Read More

252 252

Aurobindo to widen portfolio in US, enter new European markets in 3 to 4 years

Aurobindo Pharma has said it would broaden product portfolio in the US while entering new markets in Europe as part of its growth strategy over the next 3-4 years. In the US, it plans to broaden portfolio through accelerated growth in injectable, OTC and higher complexity products, Aurobindo ...

Read More

253 253

Centre plans to sell generic medicines at fuel stations

NEW DELHI: The government is working on opening 'Jan Aushadhi' (generic medicines) stores at petrol pumps belonging to state-run fuel retailers across the country with a view to make cheap drugs accessible to masses, Union oil minister Dharmendra Pradhan said on Wednesday.  "...

Read More

254 254

China's Fosun, Shanghai Pharma bid for stake in US based drugmaker Arbor

A unit of China's Fosun Group and Shanghai Pharmaceuticals Holding Co are among bidders for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals LLC, the companies said on Monday. The bids come as Chinese companies face tightening scrutiny on their overseas investments. Chinese regul...

Read More

255 255

Divi's Lab gets green nod for Rs 100cr modernisation project

NEW DELHI: Divi's Laboratories has received environment clearance for modernisation of its bulk drug unit in Visakhapatnam which will entail a cost of Rs 100 crore.  The company wants to modernise one of the two units by shifting non-production activities to proposed new area and mee...

Read More

256 256

Intas eyes Teva’s oncology, women’s health divisions in Europe

MUMBAI: Within a year of buying out Teva's UK and Ireland assets and breaking into the top 20 generics players club, Intas Pharmaceuticals is on the prowl again for a larger piece of Teva’s existing operations in Europe.  The closely held Ahmedabad-based drug maker, which has T...

Read More

257 257

Aurobindo Pharma ups the ante in oncology space

Aurobindo Pharma, one of the country’s leading drug makers, plans to develop “more than 58 drugs” in the oncology space, besides eight hormone products, and could start regulatory filings for them later this year. Manufacturing of these drugs would commence from 2018-19, the com...

Read More

258 258

Wockhardt's antibiotic injection gets USFDA nod

NEW DELHI: Drug firm Wockhardt has received approval from the US health regulator for its generic Oxacillin injection used for treatment of bacterial infections, the company said today.  The company has received approval from the United States Food and Drug Administration (USFDA) for its...

Read More

259 259

Centre mulls waiving off clinical trials on humans for critical drugs

NEW DELHI: In a move to make innovative medicines available for critical diseases like HIV, hepatitis and tuberculosis, the health ministry plans to waive off clinical trials in humans for select drugs which are essential for Indian patients and were approved in developed markets like the US, Eur...

Read More

260 260

NPPA moves to prevent distributors from taking higher cuts on stents

NEW DELHI: India’s drug pricing watchdog has moved to plug a loophole that may have helped some distributors grab higher profits on cardiac stents than the government has allowed.  A cardiac stent is a wire mesh tube used to clear blockages in coronary arteries and prevent heart at...

Read More

261 261

GST hiccups stay for distributors, chemists

One month after the roll out of the goods and services tax (GST), the stocking of medicines has not stabilised. Chemists in Delhi said they were not comfortable packing their shelves because incentives provided to them in the pre-GST regime were no longer on offer. “Most companies a...

Read More

262 262

Panacea Biotec enters collaboration with Bionpharma for generics worth $800 million

NEW DELHI: Indian biotech firm Panacea Biotec has entered into a joint collaboration with US generic drug maker Bionpharma Inc to develop, manufacture and sell seven complex generic drugs, the company said. Panacea declined to specify the drugs that would be developed under this collaboration, bu...

Read More

263 263

Mylan Pharma launches chronic hepatitis C drug in India

Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N V, announced on Thursday, the launch of Velpatasvir 100 mg/Sofosbuvir 400 mg tablets under the brand name MyHep All in India. MyHep All is a fixed-dose combination tablet indicated for the treatment of chronic hepatitis C virus in...

Read More

264 264

Russia’s Chelyabinsk woos Indian pharma

Russia’s Chelyabinsk region is seeking proposals from Indian pharmaceutical companies looking to set up manufacturing units there with a local partner. While some manufacturers are eyeing the prospect of a local production facility as it would translate into easier and greater access to...

Read More

265 265

Cipla's newly launched drug to cure severe malaria in young children

Drug major Cipla in partnership with Medicines for Malaria Venture (MMV) on Tuesday launched a drug used for the treatment of severe malaria in young children. The company introduced 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention fo...

Read More

266 266

Lupin gets USFDA nod to market skin lotion

Drug firm Lupin on Monday said it has received final approval from the US health regulator to market its Fluocinonide topical solution used for the treatment of various skin conditions. The company has received final approval to market generic Fluocinonide Topical Solution USP, 0.05 per cent ...

Read More

267 267

Swine flu threat grows; 600 deaths, 12,500 cases this year

NEW DELHI: Swine flu, the viral illness that became a pandemic in 2009, has made a comeback this year, claiming nearly 600 lives across the country so far this year with close to 12,500 cases being reported. Maharashtra is the worst affected with 284 deaths followed by Gujarat (75), Kerala (6...

Read More

268 268

Spanish scientists discover molecule for potential drug to cure Zika virus

Researchers from a southeastern Spanish university announced the discovery of a molecule that could be used as a potential drug to fight the effects of a Zika virus infection. In a statement on Saturday, the San Antonio Catholic University of Murcia (UCAM) said that scientists belonging to it...

Read More

269 269

Less than one doctor for 1000 population in India: Government to Lok Sabha

NEW DELHI: India has less than one doctor for every 1000 population which is less than the World Health Organisation standard, the Lok Sabha was informed today.  Minister of State for Health Anupriya Patel said as per information provided by the Medical Council of India, there were a tot...

Read More

270 270

India, China, Pakistan among 10 nations accounting for 95 percent of HIV infections: UN report

UNITED NATIONS: India, China and Pakistan are among the 10 countries that accounted for more than 95 per cent of all new HIV infections in the Asia and the Pacific region in 2016, according to a UN report.  The report by the Joint UN Programme on HIV/AIDS, UNAIDS, 'Ending AIDS: Progr...

Read More

271 271

Merck sees market for novel therapies, to focus on its oncology pipeline

MUMBAI: Merck is betting on India's growing pharmaceutical space and steady state spending on healthcare to expand its business, even as the German life sciences and technology company's seven-year-old joint venture with Dr Reddy's Laboratories to develop biosimilar drugs comes to an ...

Read More

272 272

Glenmark, Cyndea Pharma to develop complex drugs for US, Canada markets

Glenmark has tied up with Spanish firm Cyndea Pharma to develop complex drugs for US and Canada markets. Following the tie up Glenmark will develop soft-gelatin capsule products under the technology license from the Spanish drug maker. The partnership allows Glenmark to expand its dosage form...

Read More

273 273

GSK puts old antibiotics and UK Horlicks biz on the block

GlaxoSmithKline said it was considering the sale of its cephalosporins antibiotics business and intended to divest its small Horlicks business in Britain, while retaining the much bigger malted drink operation in India.  The antibiotics business under strategic review covers the brands Z...

Read More

274 274

Cadila new MD Shravil Patel aims to double revenues in 5 years

MUMBAI: At 38, Shravil Patel, the newly appointed managing director at Cadila Healthcare, might be the youngest among top pharma executives. But with the backing of his father, the aggressive pharma veteran Pankaj Patel, Shravil says he would aim to double the company's revenue -more than Rs ...

Read More

275 275

Despite pricing pressure, pharma exports to US may rise in FY18: Report

Despite pricing pressure and stiff competition, the Indian Pharma exports to the USA may go up in 2017-18 as $50 billion worth of drugs are expected to become off-patented during the current year giving hope to boost the export market, said a report by Care Ratings. "The Indian pharmaceu...

Read More

276 276

Dr Reddy, Lupin, others mull expanding Africa operations

Domestic pharmaceutical companies are expanding their Africa operations with product launches in new markets. In FY17, Indian drugmakers exported medicines worth $3 billion to Africa and the continent is the second-largest export market for Indian companies after the United States. Accord...

Read More

277 277

Alembic Pharma opens Rs 300cr anticancer drug unit in Gujarat

Drug firm Alembic Pharmaceuticals Ltd (APL) on Friday entered into oncology segment by inaugurating a Rs 300 crore anti-cancer drug facility at Halol in Gujarat. Speaking on the occasion, Chirayu Amin chairman of Alembic group of companies said the Rs 300 crore unit will manufacture 60 millio...

Read More

278 278

Big boost for Biocon as USFDA Onco committee approves company's first breast cancer biosimilar drug

MUMBAI: The US Food and Drug Administration on Friday approved Biocon and US drug maker Mylan's proposed biosimilar breast cancer drug Trastuzumab, a move that opens doors for Bangalore based Biocon in the big league of US cancer drug market.  The USFDA's Oncology Drugs Advisory ...

Read More

279 279

US regulatory nod for Zydus drug to treat dementia

The US Food and Drug Administration has approved a drug by Zydus Cadila used to treat dementia of the Alzheimer's type, the Indian pharmaceutical company said on Wednesday. "We have received the final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5 mg and 10 ...

Read More

280 280

Dr Reddys, Lupin, others mull expanding Africa operations

Domestic pharmaceutical companies are expanding their Africa operations with a series of product launches, besides planning to foray in new markets. In FY 2017, drug makers exported medicines worth $ 3 billion to Africa and the continent is the second largest export market for Indian companie...

Read More

281 281

Alembic Pharma gains 6 percent on USFDA nod for new drug

Alembic pharmaceuticals  rose 6% to Rs 545 on BSE in intra-day trade after the company said that it has received US Food & Drug Administration (USFDA) tentative approval for its abbreviated new drug application (ANDA) for Dabigatran Etexilate Capsules, 150 mg. “The tenta...

Read More

282 282

Lupin plans to consolidate generic products

Drug major Lupin is devising plans to consolidate its generic portfolio across key geographies, including the US, with a focus on expansion of complex and specialty products. The Mumbai-based company may look at acquisitions, besides enhanced investment in research and development (R&D), ...

Read More

283 283

GSK to invest Rs 1,000 cr in Karnataka for new plant

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd is investing Rs 1,000 crore in a new state-of-the-art pharmaceutical unit in Karnataka and is looking at enhancing its global pipeline in areas like respiratory drugs and vaccines in India. "We are investing Rs 1,000 crore in ...

Read More

284 284

Sun Pharma enters settlement in antitrust litigation in US

NEW DELHI: Indian pharmaceutical giant Sun Pharmaceutical Industries LtdBSE 0.88 % and one of its wholly-owned subsidiaries have entered into settlements with “certain plaintiffs” in an antitrust litigation matter currently pending in the United States, the company said.  Sun...

Read More

285 285

Glenmark gets US FDA nod for high blood pressure medicine

NEW DELHI: The US arm of Indian pharmaceutical major Glenmark PharmaceuticalsBSE 1.61 % has been granted final approval by the United States Food and Drug Administration (US FDA) for its generic version of Japanese drug maker Daiichi Sankyo’s Azor tablets. Azor—amlodipine and olmesart...

Read More

286 286

Stronger rupee dampens pharma firms profit

Domestic pharmaceutical companies, says Edelweiss Securities Research, will see profit erosion in the June quarter, due to pricing pressure and strengthening of the rupee against the dollar over the past year. The latter development means Indian companies earn less in rupee terms for their fo...

Read More

287 287

FSSAI panel to address concerns on health supplements nutraceuticals

The Food Safety and Standards Authority of India (FSSAI) on Thursday said it is in the process of addressing concerns raised by the industry on new standards for eight categories of products, including health supplements and nutraceuticals, which were notified in 2016. "These standards w...

Read More

288 288

GST impact Pharma sector supply chain coping well after rollout

Drug manufacturer Biocon on Thursday said most of the supply chain in pharmaceuticals sector seems to be coping after the implementation of the Goods and Services Tax (GST) system from July 1. "Most of the supply chain seems to be coping... the kind of apprehension expressed by stockists...

Read More

289 289

Government notifies 15 medical devices as drugs for price regulation

NEW DELHI: Bringing critical medical devices like stents, orthopaedic implants and diagnostic equipment under stringent regulation, the health ministry has notified Medical Devices Rules, 2017, which will come into effect from January, 2018. The government has also notified 15 devices as drugs to...

Read More

290 290

Novartis receives EU approval for Cosentyx label update

ZURICH: NovartisBSE -0.41 % said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis  The label update includes 52-week data from the CLEAR study demonstratin...

Read More

291 291

Jubilant Life Sciences gets USFDA nod for antidepressive drug

NEW DELHI: Drug firm Jubilant Life SciencesBSE 0.47 % today said its subsidiary has received final approval from the US health regulator for Bupropion Hydrochloride extended- release tablets, used for the treatment of major depressive disorder and prevention of seasonal affective disorder.  ...

Read More

292 292

Desi pharma companies need not fear Amazon in US

MUMBAI: Indian generic companies that retail in the US can breathe easy . Amazon's reported entry in the US pharmacy business does not pose a challenge to these companies that export substantial amounts to that country , even as the e-tailing giant has managed to disrupt the market in most co...

Read More

293 293

Zydus starts phase II trials of molecule targeting anaemia

NEW DELHI: Drug firm Zydus Cadila today announced the initiation of a phase II trial of oral small molecule Zyan1 that has been designed for the treatment of anaemia associated with chronic kidney disease.  Zyan1 has been designed to increase the natural production of hemoglobin and RBCs...

Read More

294 294

Sun Pharma inks USD 55.5mn deal with Samsung BioLogics for antipsoriasis drug

Sun Pharma and Samsung BioLogics on Tuesday announced a strategic long-term manufacturing agreement for Tildrakizumab used for treatment of psoriasis. "The agreement was entered into by Sun Pharma's wholly- owned subsidiary and Samsung BioLogics...Sun Pharma...

Read More

295 295

Swine Flu: Govt relaxes norms for availability of H1N1 drugs

Antiviral drugs for treating Swine Flu will soon be available at a chemist shop near you, with the government relaxing norms on their availability. A recent directive by the Ministry of Health said 'Oseltamivir Phosphate' and 'Zanamivir' drugs have now been included in the Sch...

Read More

296 296

India launches flagship program to boost biopharma production

NEW DELHI: India's biopharmaceuticals industry has received a booster dose from the government, with the Ministry of Science and Technology having finally launched its $250-million program to promote the production of biological drugs here. The program, first approved by the union cabinet in ...

Read More

297 297

GST launch at midnight: No change in cost of 78 percent of actively used drugs

Drug pricing regulator NPPA today said prices of around 78 per cent of 'actively used' drugs will remain unaffected after the rollout of the Goods and Services Tax (GST) from midnight tonight. The National Pharmaceutical Pricing Authority (NPPA) has already announced provisional ceili...

Read More

298 298

Worldwide drug sales to hit $ 1.06 trillion in 2022: Study

Increased scrutiny around the pricing of medicines is starting to have an impact on drug sales growth, according to Evaluate’s latest World Preview report. Despite consensus forecasts for worldwide drug sales hitting $ 1.06 trillion in 2022, this is down from the $ 1.12 trillion analysts fo...

Read More

299 299

US FDA approves Natco Pharma's anti cancer drug azacitidine

Natco Pharma Limited has received final approval from the US Food and Drug Administration (FDA) for azacitidine injection used in the treatment of cancer. “Natco Pharma Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US FDA for azacitidine f...

Read More

300 300

Sun Pharma to develop chikungunya, zika drugs

Sun Pharmaceutical Industries has tied up with Pune-based National Institute of Virology to develop new drugs to treat chickungunya, dengue and zika. The partnership is a part of company's plans to develop drugs which cater to unmet needs of patients. Currently there are no specific drugs...

Read More

301 301

Drugs for cancer, diabetes, rare diseases to get affordable after GST roll out on July 1

The goods and services tax (GST) is unlikely to be a very bitter pill for the pharmaceutical industry, which feared a substantial rise in drug prices under the new indirect tax regime. While around 80 per cent drugs were put in the 12 per cent GST bracket (up from the current 9 per cent slab), im...

Read More

302 302

Biological E to make two of Takeda's vaccines for India and China markets

Japanese global pharmaceutical company Takeda and Hyderabad-based vaccine maker Biological E. Limited(BE) announced on Monday that they have entered into a collaboration under which two licensing agreements to expedite the development and delivery of affordable combination vaccines have been exec...

Read More

303 303

D B Gupta, who borrowed Rs 5,000 from wife to set up Lupin, is dead

Lupin founder-chairman Desh Bandhu Gupta, who transformed the company from a tuberculosis drugs specialist in the 1980s to a global leader in generic drugs, passed away in Mumbai on Monday. He was 79 and is survived by a wife and five children. Gupta founded Lupin in 1968, borrowing Rs 5,000 ...

Read More

304 304

US FDA approves Glenmark Pharma's drug for overactive bladder

Glenmark Pharmaceuticals on Thursday said the US health regulator has granted tentative approval for tablets used for treatment of overactive bladder. The company has been granted tentative approval by the United States Food and Drug Administration (US FDA) for Solifenacin Succinate tablets,...

Read More

305 305

US FDA approves Alembic Pharma's drug to treat infection, parkinsonism

Drug firm Alembic Pharmaceuticals has received US health regulator's nod for Amantadine Hydrochloride capsules used to treat symptoms of infection caused by influenza virus. "The company has received approval from the United States Food and Drug Administration (USFDA) for its A...

Read More

306 306

Sun Pharma's extra discount to tide over GST wave

Sun Pharmaceuticals’ promoter Aditya Medisales has written to all stockists of the company’s products telling them that they will get extra discount, especially in the consumer health segment. This is an attempt to ensure that its products are available even with t...

Read More

307 307

Department of Pharmaceuticals sets up facilitation cell to help firms shift to GST

NEW DELHI: The Department of Pharmaceuticals (DoP) has constituted a GST facilitation centre to enable pharma companies to successfully implement the new tax regime.  "In order to help and support the pharmaceutical industry in ensuring smooth and successful rollout of GST, a facili...

Read More

308 308

Global pharma sales face $60 bn hit due to pricing scrutiny market study

Market intelligence firm Evaluate has cut the 2022 global pharmaceutical sales forecast by $60 billion amid rising scrutiny of drug pricing and price erosion in various markets.   A report by the firm states that patent expiries of drugs valuing $194 billion will...

Read More

309 309

Zydus Cadila gets USFDA nod to market migraine drug

NEW DELHI: Drug firm Cadila HealthcareBSE 1.09 % today said Zydus Cadila has received an approval from the US health regulator to market Eletriptan Hydrobromide tablets used in treatment of migraine.  "Zydus Cadila has received the final approval from the United States Food and Drug...

Read More

310 310

Aurobindo Pharma gets USFDA nod for oral suspension

NEW DELHI: Drug firm Aurobindo Pharma has received USFDA nod to make oral suspension used for controlling serum phosphorus in patients with chronic kidney disease on dialysis.  The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelam...

Read More

311 311

Working to get generic drugs exempt from GST: Ananth Kumar

Even as pharmaceutical companies prepare themselves to come under the GST ambit from July 1, Pharmaceuticals Minister Ananth Kumar on Tuesday said the Department of Pharmaceuticals was trying to get generic medicines exempt from GST. These are the drugs sold at Janaushadhi stores, which provide a...

Read More

312 312

10 percentage hike too little, we want more to offset GST impact, say pharma players

The pharmaceutical industry has sought permission to increase prices of non-scheduled drugs by more than the stipulated 10 per cent in a year, as the tax rate on most drugs was raised to 12 per cent under the proposed GST regime from the current nine per cent. In a meeting...

Read More

313 313

US FDA grants approval for ezetimibe tablet to Sun Pharma & Zydus Cadila

The US Food & Drug Administration has granted marketing approval for ezetimibe tablet (10 mg) to two Indian companies - Sun Pharma and Zydus Cadila. Ezetimibe, a generic version of Merck’s Zetia tablet, is used to reduce high cholesterol levels. ...

Read More

314 314

Aurobindo Pharma looks to sell cancer drugs in the US by year end

Hyderabad-based Aurobindo Pharma Limited is hoping to receive three-four product approvals in the oncology space from the US Food and Drug Administration (US FDA) before March 2018. The company's optimistic prediction about a possible good start in this high-margin pro...

Read More

315 315

Zydus' Nesher Pharma gets US FDA nod for antifungal drug

Zydus Group firm Cadila Healthcare’s subsidiary Nesher Pharmaceuticals has received nod from the USFDA to market Nystatin topical powder used for treating skin infections in the US market. The drug will be produced at Nesher Pharmaceuticals manufacturing facility in USA, the company said in...

Read More

316 316

Top five Indian pharma companies together spent over Rs 8000 crore on R&D spend in FY17

Indian drugmakers have a potent cure for the present ills dogging the industry: Research  Often pulled up for spending too little on research and development (R&D), India’s biggest pharmaceutical companies now appear to match their global peers in investing for the future. The ...

Read More

317 317

FDA nod for generic Lialda launch to boost US biz for Zydus Cadila in FY18

Ahmedabad-headquartered pharma major Zydus Cadila has got the final nod from the US drug regulator to market Mesalamine tablets in the US. The ulcerative colitis drug is estimated to have a market size of $1.145 billion. While most p...

Read More

318 318

Drug shortages likely during tax transition

Shortages are likely as the pharmaceutical industry gears up for transitioning to the GST from July 1. The stockist-level inventory at the end of May was lower than that in April as most companies drew down stocks at the distributor level.  According to the All I...

Read More

319 319

Nearly half of pharma industry may come under price control

Fixed-dose combinations (FDCs), drugs that include two or more therapeutic ingredients, comprise nearly 40 per cent of Indian drug market, say industry bodies that fear the move of National Pharmaceutical Pricing Authority (NPPA) putting them under price control. The drug pricing authority last m...

Read More

320 320

Dilip Shanghvi repositions Sun Pharma in US as a specialty drugmaker

Investors in Sun Pharmaceutical have lost about Rs 25,000 crore in the last two weeks since its US subsidiary Taro Pharmaceutical announced 32% annual decline in net profit to $83 million for quarter ending March 2017. Net sales for the subsidiary declined 26% to $196 million for the period. Parent ...

Read More